Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer

Annals of Oncology

Volumn 5, Issue SUPPL. 7, 1994, Pages 19-24

  Perez Carrion, P ^a   Alberola Candel, V ^a   Calabresi, F ^a   Michel Th , R ^a   Santos, R ^a   Delozier, T ^a   Goss, P ^a   Mauriac, L ^a   Feuilhade, F ^a   Freue, M ^a   Pannuti, F ^a   van Belle, S ^a   Martinez, J ^a   Wehrle, E ^a   Royce, C M ^a  

^a CIBA GEIGY LTD   (Switzerland)

Author keywords

Aromatase inhibition; Endocrine therapy; Formestane; Lentaron ; Postmenopausal breast cancer; Tamoxifen

Indexed keywords

FORMESTANE; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESPONSE; FEMALE; FLUSHING; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LETHARGY; MAJOR CLINICAL STUDY; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; RASH; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS; AROMATASE; BREAST NEOPLASMS; COMPARATIVE STUDY; FEMALE; HUMAN; MIDDLE AGE; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 0028131860     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (0)